Docoh
Loading...

104 filings

Newest first
Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
FGEN FibroGen Inc
7 Apr 21
Regulation FD Disclosure
8-K
FGEN FibroGen Inc
6 Apr 21
Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat
8-K
FGEN FibroGen Inc
1 Mar 21
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
8-K
FGEN FibroGen Inc
26 Jan 21
Entry into a Material Definitive Agreement
8-K
FGEN FibroGen Inc
18 Dec 20
FibroGen Provides Regulatory Update on Roxadustat
8-K
FGEN FibroGen Inc
1 Dec 20
Departure of Directors or Certain Officers
8-K
FGEN FibroGen Inc
12 Nov 20
Entry into a Material Definitive Agreement
8-K
FGEN FibroGen Inc
5 Nov 20
FibroGen Reports THIRD Quarter 2020 Financial Results
8-K
FGEN FibroGen Inc
6 Aug 20
FibroGen Reports SECOND Quarter 2020 Financial Results
8-K
FGEN FibroGen Inc
6 Aug 20
FibroGen Announces New Appointments to its Board of Directors
8-K
FGEN FibroGen Inc
10 Jul 20
Entry into a Material Definitive Agreement
8-K
FGEN FibroGen Inc
23 Jun 20
Departure of Directors or Certain Officers
8-K
FGEN FibroGen Inc
9 Jun 20
Submission of Matters to a Vote of Security Holders
8-K
FGEN FibroGen Inc
7 May 20
FibroGen Reports First Quarter 2020 Financial Results
8-K
FGEN FibroGen Inc
24 Mar 20
Master Supply Agreement
8-K
FGEN FibroGen Inc
2 Mar 20
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
8-K
FGEN FibroGen Inc
13 Feb 20
Departure of Directors or Certain Officers
8-K
FGEN FibroGen Inc
11 Feb 20
FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease
8-K
FGEN FibroGen Inc
30 Jan 20
Astellas Submits Supplemental New Drug Application for Approval of
8-K
FGEN FibroGen Inc
13 Jan 20
Regulation FD Disclosure